Endocrine Disorder in Children with Chronic Liver Diseases

Document Type : Research Paper


1 Associate Professor of Pediatric Gastroenterology, Mashhad University of Medical Sciences, Mashhad, Iran

2 Professor of Pediatrics, Mashhad University of Medical Sciences, Mashhad, Iran

3 Assistant Associate Professor of Pediatric Gastroenterology, Mashhad University of Medical Sciences, Mashhad, Iran

4 Medical doctor, Mashhad University of Medical Sciences, Mashhad, Iran

5 Assistant Professor of Pediatrics, North Khorasan University, Bojnourd, Iran

6 MSN, Faculty member of North Khorasan university, Phd candidate of Mashhad University of Medical Sciences, Mashhad, Iran


An important consequence of chronic liver disease (CLD) is endocrine disorders. The main object of this study was to assess serum hormones in children with CLD.
Materials and Methods
In a cross sectional study between 2007-2009 ,57 children with chronic liver disease were enrolled. Levels of serum triiodothyronine (T3) , thyroxin (T4) , thyroid stimulating hormone (TSH) , parathormon (PTH), calcium(c), phosphor (P) ,alkalanephosphatase (ALP),growth hormone(GH) and insulin like growth factor-1(IGF-1) , albumin (ALB) and total protein , triglyceride (TG) and cholesterol (CHOL) , fasting blood sugar (FBS) and liver function tests were measured.
In this study, most patients' thyroid hormones and fasting blood sugar were at normal range. But there was a significant decline in serum IGF- 1 levels in this patients. 28 percent of children had PTH levels higher than normal range for age and 24 percent had serum phosphor levels lower than normal range .1/3 of these patients were bone fracture . Overt diabetics did not obsereve in our children.
Children with CLD are GH resistant and might be at risk of osteopenia and bone fracture. So serum hormone levels should be carefully monitored in children with CLD.


1- Kolia Z. Translation and validation of the Greek chronic liver disease questionnaire. World J Gastroenterol 2010;
2- Lehner S. Prognostic parameters and risk stratification in intensive care patients with severe liver diseases. J
Gastrointestin Liver Dis 2010; 19:399-404.
3- Wright T. Introduction to chronic hepatitis B infection. Am J Gastroenterol 2006; 101:S1-6.
4- Cholongitas E. Risk factors, sequential organ failure assessment and model for end-stage liver disease scores for
predicting short term mortality in cirrhotic patients admitted to intensive care unit. Aliment Pharmacol Ther 2006;
5- Conchillo M. Insulin–like growth factor 1)IGF-1) and liver cirrhosis: results of a pilot zandomized controlled
clinical trial. J Hepatol 2005; 43:630-636.
6- Ripap A. The relationship between insulin secretion, the insulin – like growth factor axis and growth in children
with cystic fibrosis. Clin Endocrinol 2002; 56:383-389.
7- Uslu N. Bone mineral density in children with cirrhosis. J Gastroenterol 2006; 41:873-877.
8- Alavian S. Prevalence and determinants of diabetes mellitus among Iranian patients with choronic liver disease.
BMC Endocr Disord 2004; 4:4-11.
9- Zein N. Prevalence of diabetes mellitus in pateint with end-stage liver cirrhosis due to hepatitis c, alchol, or
cholestatic disease. J Hepatol 2000; 32:209-217.
10-Taveira A. Longitudinal evaluation of hepatic osteodystrophy in children and adolescents with chronic cholestatic
liver disease .Braz J Med Biol Res 2010; 43:1127-1134.
11-Yuse-Gabriel C.Sex steroid hormones, growth and puberty in children with portal hypertension..J Pediatr
Endocrinol Metab 2004; 17:607-613.
12-Hepner G, Chopra I. Serum thyroid hormone levels in patients with liver disease. Arch Intern Med 2003; 139:
13-Sarkhy A, Persad R, Tarnopolsky M. Muscle weakness in a girl with autoimmune hepatitis and Graves' disease. Eur
J Pediatr 2009; 168:241-243.
14-Monajemzadeh M .Liver needle biopsy in Iraninan pediatric patients: Diagnostic significance and pattern of liver
diseases.Indian J Pathol Microbiol 2009; 52:10-13.
Shirazi M, Ameri A, Shafaroodi H, Motahhary P, Saleh T, Ghasemi M, Dehpour AR. Orthodontic tooth movement in
cholestatic and cirrhotic rats. J Orthod 2008; 35: 119-125.
15-GasserR. Cholestasis and metabolic bone disease - aclinical review. Wien Med Wochenschr 2008; 158:553- 557.
16-Sylvester F. An update on bone abnormalities associated with gastrointestinal and liver disease .Endocrinologist
2001; 11:77-85.
17-Leslie W, Bernstein C, Leboff M. AGA technical review on osteoporosis in hepatic disorders.Gastroenterology
18-Ormarsdottir S, Loof L. Increased rate of bone loss at the femoral neck in patients with hronic liver disease .Eur J
Gastroenterol Hepatol 2002; 14:43-48.
19-Hogler W, Baumann U, Kelly D. Growth and bone health in chronic liver disease and following liver transplanta in
children. Pediatr Endocrinol Rev 2010; 7:266-274.
20-Pereira F. Etiopathogenesis of hepatic osteodystrophy in wistar rate with cholestatic liver disease. Calcif Tissue Int
2009; 85:75-83.
21-Yakar s, Rosen c. From mouse to man: redefining the role of insulin- like growth factor-I in the acquisition of bone
mass. Exp Biol Med 2003; 228:245-252.
22-Taveria A. Impairement of bone mass development in children with choronic cholestatic liver diseaes. Clin
Endocrinol 2004;15:58-523.